Tumor Lysis Syndrome
Dr. Andrew Hong outlines the basics of tumor lysis syndrome, key laboratory and clinical findings, and how to prevent and manage hyperuricemia and electrolyte abnormalities due to TLS. He also identifies risk-factors for this syndrome and guides the learner through two detailed cases
Learning Objectives
Define tumor lysis syndrome
Understand the population of oncology patients at high risk for TLS - Understand range of TLS therapies
Learn how to differentiate between MOA of allopurinol and rasburicase
Management of TLS
Author(s)
Andrew L. Hong, MD
Associate Professor, Department of Pediatrics | Emory University School of Medicine
Oncologist | Children's Healthcare of Atlanta
Instructor of Pediatrics | Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Sarah Marcley, RN, BSN
Medical Video Editor, OPENPediatrics | Boston Children's Hospital
Katherine R. Schlosser Metitri, MD
Pediatric Critical Care Specialist | Columbia University
Vice President, Operations | NewYork-Presbyterian Morgan Stanley Children’s Hospital
Citation
Hong A, Marcley S, Schlosser K. Tumor Lysis Syndrome. 12/2020. Online Video. OPENPediatrics. https://learn.openpediatrics.org/learn/course/internal/view/elearning/4938/Tumor-Lysis-Syndrome.